Phaseline

Targets › TNFSF11

TNFSF11 (Tumor necrosis factor ligand superfamily member 11): drug programs, companies and trials

4 programs from 4 companies in 30 trials: 15 Phase 4, 9 Phase 2, 5 Phase 3, 1 Phase 1; Metabolic and endocrine, Oncology, Genitourinary; next expected readout Dec 2026.

Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. (UniProt, O14788)

Open in Phaseline: the race on TNFSF11, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AmgenDenosumab
Tumor necrosis factor ligand superfamily member 11 inhibitor
TNFSF11Phase 4Osteoporosis; Glucocorticoid-induced Osteoporosis; Giant Cell Tumor of Bone; Osteoporosis, Postmenopausal …Jan 2027
Qilu PharmaceuticalDenosumab (QL1206)
Tumor necrosis factor ligand superfamily member 11 inhibitor
TNFSF11Phase 3Postmenopausal Women With Osteoporosis at High Risk of FractureJan 2027
Luye Pharma GroupLY06006
RANKL inhibitor
TNFSF11Phase 3Osteoporosis, Postmenopausal–
Fudan UniversityNarlumosbart
Anti-RANKL monoclonal antibody (IgG4)
TNFSF11Phase 2NSCLCDec 2026

Conditions

Osteoporosis (7) Osteoporosis, Postmenopausal (2) Breast Cancer (2) Postmenopausal Women With Osteoporosis at High Risk of Fracture (1) NSCLC (1) Glucocorticoid-induced Osteoporosis (1) Giant Cell Tumor of Bone (1) Kidney Diseases (1) Sarcopenia in Elderly (1) Cystic Fibrosis (1) Postmenopausal Osteoporosis (1) Fibrous Dysplasia (1)

Modalities

antibody (3), small molecule (1)

Companies

Qilu Pharmaceutical (1) Fudan University (1) Amgen (1) Luye Pharma Group (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.